Systematic review: Pentoxifylline for the treatment of severe alcoholic hepatitis

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 9, 2013, Pages 845-854

  Parker, R ^a,b   Armstrong, M J ^a,b   Corbett, C ^a,b   Rowe, I A ^a,b   Houlihan, D D ^a,b  

^a University of Birmingham   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PENTOXIFYLLINE; PLACEBO; PREDNISOLONE;

ALCOHOL LIVER DISEASE; BRAIN DISEASE; CHRONIC DISEASE; DIARRHEA; DISEASE SEVERITY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; EPIGASTRIC PAIN; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEPATORENAL SYNDROME; HUMAN; INCIDENCE; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEAKNESS;

HEPATITIS, ALCOHOLIC; HUMANS; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84875866911     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12279     Document Type: Review

References (37)

1. O'Shea RS, Dasarathy S, McCullough AJ,. Alcoholic liver disease. Hepatology 2010; 51: 307-28.
2. Lucey MR, Mathurin P, Morgan TR,. Alcoholic hepatitis. N Engl J Med 2009; 360: 2758-69.
3. Sandahl TD, Jepsen P, Thomsen KL, et al,. Incidence and mortality of alcoholic hepatitis in Denmark 1999-2008: a nationwide population based cohort study. J Hepatol 2011; 54: 760-4.
4. Maddrey WC, Boitnott JK, Bedine MS, et al,. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75: 193.
5. Mathurin P, O'Grady J, Carithers RL, et al,. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011; 60: 255-60.
6. Mathurin P, Lucey MR,. Management of alcoholic hepatitis. J Hepatol 2012; 56 (Suppl. 1): S39-45.
7. EASL. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012; 57: 399-420.
8. Coffin PO, Sharpe BA,. Cause of death in alcoholic hepatitis. J Hosp Med 2007; 2: 51-2.
9. Yu CH, Xu CF, Ye H, et al,. Early mortality of alcoholic hepatitis: a review of data from placebo-controlled clinical trials. World J Gastroenterol 2010; 16: 2435.
10. Verma S, Ajudia K, Mendler M, et al,. Prevalence of septic events, type 1 hepatorenal syndrome, and mortality in severe alcoholic hepatitis and utility of discriminant function and MELD score in predicting these adverse events. Dig Dis Sci 2006; 51: 1637-43.
11. Epstein FH, Tilg H, Diehl AM,. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 343: 1467-76.
12. McClain CJ,. Tumor necrosis and alcoholic hepatitis. Hepatology 1991; 14: 394-6.
13. Naveau S, Chollet-Martin S, Dharancy S, et al,. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39: 1390-7.
14. Boetticher NC, Peine CJ, Kwo P, et al,. A randomized, double-blinded, placebo-controlled multi-center trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135: 1953.
15. Semmler J, Gebert U, Eisenhut T, et al,. Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity. Immunology 1993; 78: 520-5.
16. McHutchison JG, Runyon BA, Draguesku JO, et al,. Pentoxifylline may prevent renal impairment (hepatorenal syndrome) in severe acute alcoholic hepatitis. Hepatology 1991; 14: 96A.
17. Whitfield K, Rambaldi A, Wetterslev J, Gluud C,. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev 2009; 4: CD007339.
18. Humaidan P, Polyzos NP,. (Meta)analyze this: systematic reviews might lose credibility. Nat Med 2012; 18: 1321.
19. Moher D, Liberati A, Tetzlaff J, et al,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
20. Cochrane Handbook. Chapter 8: Assessing risk of bias in included studies. In:, Higgins JPT, Altman DG, On behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group, eds. Cochrane Handbook. London: John Wiley and Sons (under Cochrane books imprint), 2008.
21. Schulz KF, Altman DG, Moher D,. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med 2010; 8: 18.
22. Hopewell S, Clarke M, Moher D, et al,. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med 2008; 5: e20.
23. Raj AS, MacDonald GA,. Does the addition of prednisone to pentoxifylline improve outcome in severe alcoholic hepatitis? J Gastroenterol Hepatol 2011; 26 (Suppl. 4): 44.
24. Louvet A, Diaz E, Dharancy S, et al,. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 2008; 48: 465-70.
25. De BK, Gangopadhyay S, Dutta D, et al,. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol 2009; 15: 1613.
26. García JRG, Hernández GS, Lõpez AM, et al,. Pentoxifilina versus esteroide en la sobrevivencia a corto plazo en hepatitis aguda alcohõlica severa. Medicina Interna de México 2012; 28: 228.
27. Kim DJ, Suk KT, Park SH, Lee HJ, KASL ASG,. Interim report: Short-term survival in patients with severe alcoholic hepatitis treated with corticosteroid vs. pentoxifylline: a non-inferiority trial. ëŒ€íœ ê°í™íšŒì§€ 2011. Available at: http://www.papersearch.net/google-link/fulltext.asp?file-name= 27404945.pdf. Accessed April 1, 2013.
28. Akriviadis E, Botla R, Briggs W, et al,. Pentoxifylline improves short term survival in severe alcoholic hepatitis: a double blind, placebo controlled trial. Gastroenterology 2000; 119: 1637-48.
29. Lebrec D, Thabut D, Oberti F, et al,. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 2010; 138: 1755-62.
30. Sidhu SS, Goyal O, Singla P, et al,. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Dig Dis Sci 2012; 57: 1664-71.
31. Paladugu H, Sawant P, Dalvi L, et al,. Role of pentoxifylline in treatment of severe acute alcoholic hepatitis-a randomized controlled trial. J Gastroenterol Hepatol 2006; 21: A459.
32. Sidhu S, Singla M, Bhatia K,. Pentoxifylline reduces disease severity and prevents renal impairment in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Hepatology 2006; 44 (Suppl. 1): 373A.
33. Mathurin P,. Addition of pentoxifylline to prednisolone for severe alcoholic hepatitis does not improve 6-month survival: results of the Corpentox trial. Hepatology 2011; 54 (Suppl. 1): 81A.
34. Louvet A, Naveau S, Abdelnour M, et al,. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007; 45: 1348-54.
35. Louvet A, Dao TM, Nahon P, et al,. Pentoxifylline does not improve short-term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomised controlled trial. J Hepatol 2012; 56: S533.
36. International Club of Ascites Guidelines. Available at: http://www.icascites.org/about/guidelines/. Accessed January, 22 2013.
37. STOPAH trial. Available at: http://www.stopah.com. Accessed January 22, 2013.